Clinical Trial

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Name: Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis — clinical trial record (NCT07203391)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TRIUMPH

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-09-29.

Trial Details

NCT Number	NCT07203391
Lead Sponsor	St Vincent's Hospital, Sydney
Conditions	Uveal Melanoma, Metastatic
Enrollment	8 participants
Start Date	2026-02-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2029-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-23